(RTTNews) - Tenax Therapeutics, Inc. (TENX) announced an expansion of its Phase 3 LEVEL program for TNX-103 or oral levosimendan, a novel treatment for pulmonary hypertension with heart failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback